This article summarized the latest R&D progress of Cefaclor, the Mechanism of Action for Cefaclor, and the drug target R&D trends for Cefaclor.

VBI Vaccines Inc., a biopharma company specializing in immunology, announced that its cancer immunotherapy vaccine candidate, VBI-1901, has begun a Phase 2b trial in patients with first recurrence glioblastoma.

This article summarized the latest R&D progress of Adenine, the Mechanism of Action for Adenine, and the drug target R&D trends for Adenine.

CCR5, or C-C chemokine receptor type 5, is a protein receptor found on the surface of certain immune cells, including T cells and macrophages.

This article summarized the latest R&D progress of Acepromazine, the Mechanism of Action for Acepromazine, and the drug target R&D trends for Acepromazine.

4D Molecular Therapeutics has begun the Dose Confirmation stage of their Phase 2 SPECTRA trial, enrolling their first patient. The trial evaluates intravitreal 4D-150 for treating diabetic macular edema.

This article summarized the latest R&D progress of Metolazone, the Mechanism of Action for Metolazone, and the drug target R&D trends for Metolazone.

CB1 receptors play a vital role in regulating various physiological processes such as pain perception, appetite, mood, memory, and motor coordination.

FluoGuide A/S is delighted with the preliminary findings from the FG001 study concerning cancer surgery guidance in head & neck cancer patients.

This article summarized the latest R&D progress of Ipratropium Bromide, the Mechanism of Action for Ipratropium Bromide, and the drug target R&D trends for Ipratropium Bromide.

C5, or the fifth component of complement, plays a crucial role in the human body's immune system.

Tango Therapeutics has received FDA clearance for its IND application for TNG348, a new USP1 inhibitor.